Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report issued on Tuesday. The brokerage set a “hold” rating on the stock.

Separately, Alliance Global Partners dropped their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Trading Up 2.5 %

AWH stock opened at $0.73 on Tuesday. The company’s 50-day moving average price is $0.84 and its 200 day moving average price is $1.35. The company has a market cap of $11.72 million, a P/E ratio of -0.50 and a beta of 1.44. Aspira Women’s Health has a 52 week low of $0.67 and a 52 week high of $5.65.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.